Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6144-6151

  Gluz, Oleg ^a   Mengele, Karin ^a   Schmitt, Manfred ^a   Kates, Ronald ^a   Diallo Danebrock, Raihana ^a   Neff, Frauke ^a   Royer, Hans Dieter ^a   Eckstein, Niels ^a   Mohrmann, Svjetlana ^a   Ting, Evelyn ^a   Kiechle, Marion ^a   Poremba, Christopher ^a   Nitz, Ulrike ^a   Harbeck, Nadia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; THIOTEPA; Y BOX BINDING PROTEIN 1; DNA BINDING PROTEIN; NUCLEAR PROTEIN; YBX1 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 74949112839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6261     Document Type: Article

References (54)

1. Day RS, Shackney SE, Peters WP: The analysis of relapse-free survival curves: Implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer. Br J Cancer 92:47-54, 2005
2. Rodenhuis S, Bontenbal M, Beex LV, et al: High-dose chemotherapy with hematopoietic stemcell rescue for high-risk breast cancer. N Engl J Med 349:7-16, 2003
3. Peters WP, Rosner GL, Vredenburgh JJ, et al: Prospective, randomized comparison of highdose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23: 2191-2200, 2005
4. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
5. Basser RL, O'Neill A, Martinelli G, et al: Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 24:370-378, 2006
6. Wilking N, Lidbrink E, Wiklund T, et al: Longterm follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18:694-700, 2007
7. Nitz UA, Mohrmann S, Fischer J, et al: Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366: 1935-1944, 2005
8. Gluz O, Nitz UA, Harbeck N, et al: Triplenegative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 19:861-870, 2008
9. Kröger N, Milde-Langosch K, Riethdorf S, et al: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12:159-168, 2006
10. Chatterjee M, Rancso C, Stühmer T, et al: The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111:3714-3722, 2008
11. Schittek B, Psenner K, Sauer B, et al: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120:2110-2118, 2007
12. Janz M, Harbeck N, Dettmar P, et al: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97:278-282, 2002
13. Kohno K, Izumi H, Uchiumi T, et al: The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25:691-698, 2003
14. Shibahara K, Sugio K, Osaki T, et al: Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7:3151-3155, 2001
15. Gessner C, Woischwill C, Schumacher A, et al: Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J 23:14-19, 2004
16. Oda Y, Ohishi Y, Basaki Y, et al: Prognostic implications of the nuclear localization of Y-boxbinding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/ MVP and P-glycoprotein expression. Cancer Sci 98:1020-1026, 2007
17. Fujita T, Ito K, Izumi H, et al: Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11:8837-8844, 2005
18. Bargou RC, Jürchott K, Wagener C, et al: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3:447-450, 1997
19. Ohga T, Uchiumi T, Makino Y, et al: Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273:5997-6000, 1998
20. Stein U, Jürchott K, Walther W, et al: Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 276:28562-28569, 2001
21. Stein U, Bergmann S, Scheffer GL, et al: YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 24:3606-3618, 2005
22. Hasegawa SL, Doetsch PW, Hamilton KK, et al: DNA binding properties of YB-1 and dbpA: Binding to double-stranded, single-stranded, and abasic site containing DNAs. Nucleic Acids Res 19:4915-4920, 1991
23. Ise T, Nagatani G, Imamura T, et al: Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 59: 342-346, 1999
24. Marenstein DR, Ocampo MT, Chan MK, et al: Stimulation of human endonuclease III by Y boxbinding protein 1 (DNA-binding protein B). Interaction between a base excision repair enzyme and a transcription factor. J Biol Chem 276:21242-21249, 2001
25. Izumi H, Imamura T, Nagatani G, et al: Y box-binding protein-1 binds preferentially to singlestranded nucleic acids and exhibits 3′- >5′ exonuclease activity. Nucleic Acids Res 29:1200-1207, 2001
26. Gaudreault I, Guay D, Lebel M: YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modi-fications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 32:316-327, 2004
27. Fujii T, Kawahara A, Basaki Y, et al: Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 68:1504-1512, 2008
28. Sutherland BW, Kucab J, Wu J, et al: Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24:4281-4292, 2005
29. Jurchott K, Bergmann S, Stein U, et al: YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278:27988-27996, 2003
30. Berquin IM, Pang B, Dziubinski ML, et al: Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 24: 3177-3186, 2005
31. Stratford AL, Habibi G, Astanehe A, et al: Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9:R61, 2007
32. Homer C, Knight DA, Hananeia L, et al: Y-box factor YB1 controls p53 apoptotic function. Oncogene 24:8314-8325, 2005
33. Wu J, Lee C, Yokom D, et al: Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66:4872-4879, 2006
34. Evdokimova V, Ruzanov P, Anglesio MS, et al: Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol 26:277-292, 2006
35. Ohga T, Koike K, Ono M, et al: Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56:4224-4228, 1996
36. Diallo-Danebrock R, Ting E, Gluz O, et al: Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13:488-497, 2007
37. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
38. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22, 2007
39. Oda Y, Ohishi Y, Saito T, et al: Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 199:251-258, 2003
40. Oda Y, Sakamoto A, Shinohara N, et al: Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4:2273-2277, 1998
41. Faury D, Nantel A, Dunn SE, et al: Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25:1196-1208, 2007
42. Giménez-Bonafé P, Fedoruk MN, Whitmore TG, et al: YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59:337-349, 2004
43. Kuwano M, Oda Y, Izumi H, et al: The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3:1485-1492, 2004
44. Huang J, Tan PH, Li KB, et al: Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol 26:607-613, 2005
45. Mantwill K, Köhler-Vargas N, Bernshausen A, et al: Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: Implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 66:7195-7202, 2006
46. Harbeck N, Alt U, Berger U, et al: Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757-2764, 2001
47. Levenson VV, Davidovich IA, Roninson IB: Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 60:5027-5030, 2000
48. Shiota M, Izumi H, Onitsuka T, et al: Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68:98-105, 2008
49. Sorokin AV, Selyutina AA, Skabkin MA, et al: Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J 24:3602-3612, 2005
50. Lu ZH, Books JT, Ley TJ: YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 25:4625-4637, 2005
51. Zander AR, Schmoor C, Kröger N, et al: Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of follow-up. Ann Oncol 19:1082-1089, 2008
52. Lasham A, Moloney S, Hale T, et al: The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 278:35516-35523, 2003
53. Braithwaite AW, Del Sal G, Lu X: Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ 13:984-993, 2006
54. Shiota M, Izumi H, Onitsuka T, et al: Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 27:5543-5553, 2008